Prohance and Paricalcitol drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Prohance (gadoteridol) and Paricalcitol (paricalcitol). Common drug interactions include pain among females and anhedonia among males.

The phase IV clinical study analyzes what interactions people have when they take Prohance and Paricalcitol. It is created by eHealthMe based on reports of 15 people who take the same drugs from the FDA, and is updated regularly.

What is Prohance?

Prohance has active ingredients of gadoteridol. eHealthMe is studying from 3,734 Prohance users. Check the latest studies of Prohance.

What is Paricalcitol?

Paricalcitol has active ingredients of paricalcitol. eHealthMe is studying from 1,278 Paricalcitol users. Check the latest studies of Paricalcitol.

On Jul, 21, 2026

15 people who take Prohance and Paricalcitol together, and have interactions are studied.

Prohance and Paricalcitol drug interactions.

What are the common drug interactions of Prohance and Paricalcitol, by gender? *:

female:

Pain
Joint range of motion decreased (disease of joint movement)
Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Oedema peripheral (superficial swelling)
Skin tightness
Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)
Skin discolouration (change of skin colour)
Skin hyperpigmentation (disorders affect the colour of your skin)
Deformity (disfigurement)
Mobility decreased (ability to move is reduced)

male:

Anhedonia (inability to experience pleasure from activities usually found enjoyable)
Anxiety
Skin tightness
Emotional distress
Joint range of motion decreased (disease of joint movement)
Mobility decreased (ability to move is reduced)
Muscular weakness (muscle weakness)
Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Pain
Skin hypertrophy (skin cells enlarges)

What are the common drug interactions of Prohance and Paricalcitol, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Joint range of motion decreased (disease of joint movement)
Nephrogenic systemic fibrosis (involves fibrosis of skin, joints, eyes due to kidney disease)
Deformity (disfigurement)
General physical health deterioration (weak health status)
Skin exfoliation (removal of the oldest dead skin cells)
Skin fibrosis (fibrous tissue formation on skin)
Skin hypertrophy (skin cells enlarges)
Anxiety
Asthenia (weakness)
Emotional distress

60+:

n/a

What are the existing conditions these people have? *

Nuclear Magnetic Resonance Imaging Brain: 9 people, 60.00%
Nuclear Magnetic Resonance Imaging Abdominal: 4 people, 26.67%
Tenderness (pain or discomfort when an affected area is touched): 1 person, 6.67%
Swelling: 1 person, 6.67%
Renal Cell Carcinoma (a kidney cancer): 1 person, 6.67%
Pain: 1 person, 6.67%
Musculoskeletal Stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves): 1 person, 6.67%
Hypotension (abnormally low blood pressure): 1 person, 6.67%
Hyperparathyroidism Secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary): 1 person, 6.67%
Clostridium Difficile Colitis (inflammation of colon by clostridium difficile bacteria infection): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Prohance and Paricalcitol?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously